Literature DB >> 21746752

Amisulpride-induced acute akathisia in OCD: an example of dysfunctional dopamine-serotonin interactions?

Karen D Ersche1, Paul Cumming, Kevin J Craig, Ulrich Müller, Naomi A Fineberg, Edward T Bullmore, Trevor W Robbins.   

Abstract

We report about a clinical observation in a well-characterized group of patients with obsessive-compulsive disorder (OCD) during an experimental medicine study in which a single dose of amisulpride (a selective D₂/₃ antagonist) was administered. Almost half of the OCD patients, in particular those with less severe obsessive-compulsive symptoms, experienced acute akathisia in response to the amisulpride challenge. This unexpectedly high incidence of akathisia in the selective serotonin reuptake inhibitor (SSRI)-treated patients with OCD suggests that individual differences in dopamine-serotonin interactions underlie the clinical heterogeneity of OCD, and may thus explain the insufficiency of SSRI monotherapy in those patients not experiencing a satisfactory outcome in symptom reduction. We further speculate about the neuropathology possibly underlying this clinical observation and outline a testable hypothesis for future molecular imaging studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21746752      PMCID: PMC3664784          DOI: 10.1177/0269881111405363

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  19 in total

1.  Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans.

Authors:  Adam R Aron; Paul C Fletcher; Ed T Bullmore; Barbara J Sahakian; Trevor W Robbins
Journal:  Nat Neurosci       Date:  2003-02       Impact factor: 24.884

Review 2.  A review of antipsychotics in the treatment of obsessive compulsive disorder.

Authors:  Naomi A Fineberg; Tim M Gale; Thanusha Sivakumaran
Journal:  J Psychopharmacol       Date:  2005-10-04       Impact factor: 4.153

3.  SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD).

Authors:  Oliver Pogarell; Gabriele Poepperl; Christoph Mulert; Christine Hamann; Nikolai Sadowsky; Michael Riedel; Hans-Juergen Moeller; Ulrich Hegerl; Klaus Tatsch
Journal:  Eur Neuropsychopharmacol       Date:  2005-10       Impact factor: 4.600

4.  The Work and Social Adjustment Scale: a simple measure of impairment in functioning.

Authors:  James C Mundt; Isaac M Marks; M Katherine Shear; John H Greist
Journal:  Br J Psychiatry       Date:  2002-05       Impact factor: 9.319

5.  Acute antipsychotic-induced akathisia revisited.

Authors:  Michael Poyurovsky
Journal:  Br J Psychiatry       Date:  2010-02       Impact factor: 9.319

6.  Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study.

Authors:  M Reimold; M N Smolka; A Zimmer; A Batra; A Knobel; C Solbach; A Mundt; H U Smoltczyk; D Goldman; K Mann; G Reischl; H-J Machulla; R Bares; A Heinz
Journal:  J Neural Transm (Vienna)       Date:  2007-08-22       Impact factor: 3.575

7.  Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial.

Authors:  Michael Poyurovsky; Artashes Pashinian; Ronit Weizman; Camil Fuchs; Abraham Weizman
Journal:  Biol Psychiatry       Date:  2006-02-21       Impact factor: 13.382

Review 8.  Akathisia and second-generation antipsychotic drugs.

Authors:  Rajeev Kumar; Perminder S Sachdev
Journal:  Curr Opin Psychiatry       Date:  2009-05       Impact factor: 4.741

9.  World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.

Authors:  Borwin Bandelow; Joseph Zohar; Eric Hollander; Siegfried Kasper; Hans-Jürgen Möller; Joseph Zohar; Eric Hollander; Siegfried Kasper; Hans-Jürgen Möller; Borwin Bandelow; Christer Allgulander; José Ayuso-Gutierrez; David S Baldwin; Robertas Buenvicius; Giovanni Cassano; Naomi Fineberg; Loes Gabriels; Ian Hindmarch; Hisanobu Kaiya; Donald F Klein; Malcolm Lader; Yves Lecrubier; Jean-Pierre Lépine; Michael R Liebowitz; Juan José Lopez-Ibor; Donatella Marazziti; Euripedes C Miguel; Kang Seob Oh; Maurice Preter; Rainer Rupprecht; Mitsumoto Sato; Vladan Starcevic; Dan J Stein; Michael van Ameringen; Johann Vega
Journal:  World J Biol Psychiatry       Date:  2008       Impact factor: 4.132

10.  Neurochemical modulation of response inhibition and probabilistic learning in humans.

Authors:  Samuel R Chamberlain; Ulrich Müller; Andrew D Blackwell; Luke Clark; Trevor W Robbins; Barbara J Sahakian
Journal:  Science       Date:  2006-02-10       Impact factor: 47.728

View more
  1 in total

1.  Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study.

Authors:  Charles R Conway; John T Chibnall; Paul Cumming; Mark A Mintun; Marie Anne I Gebara; Dana C Perantie; Joseph L Price; Martha E Cornell; Jonathan E McConathy; Sunil Gangwani; Yvette I Sheline
Journal:  Psychiatry Res       Date:  2014-01-14       Impact factor: 3.222

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.